- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | VISEN PHARMA-B (02561): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 26 JUNE 2026 AT 10:00 A.M. | 1 | HKEx | ||
| Di | VISEN PHARMA-B (02561): NOTICE OF ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Di | VISEN PHARMA-B (02561): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS; (2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES ... | 1 | HKEx | ||
| Di | VISEN PHARMA-B (02561): 2025 ANNUAL REPORT | 3 | HKEx | ||
| 22.04. | VISEN PHARMA-B (02561): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| VISEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 26.03. | VISEN PHARMA-B (02561): NOTICE OF EGM | - | HKEx | ||
| 26.03. | VISEN PHARMA-B (02561): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON APRIL 22, 2026 AT 10 A.M. | - | HKEx | ||
| 26.03. | VISEN PHARMA-B (02561): (1) REVISION AND RENEWAL OF EXISTING ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS UNDER THE EXCLUSIVE LICENCE AGREEMENTS; ... | 1 | HKEx | ||
| 12.03. | VISEN PHARMA-B (02561): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | - | HKEx | ||
| 02.03. | VISEN PHARMA-B (02561): DATE OF BOARD MEETING | - | HKEx | ||
| 20.02. | Trotz Trump-Einladung keine US-Visen für Belarus | 3 | Reuters Deutschland | ||
| 26.01. | VISEN PHARMA-B (02561): INSIDE INFORMATION ANNOUNCEMENT BIOLOGICS LICENSE APPLICATION FOR LONAPEGSOMATROPIN FOR INJECTION APPROVED BY THE NMPA | 1 | HKEx |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 16,115 | -24,94 % | Summit Therapeutics falls after update on Akeso-partnered lung cancer trial | ||
| ERASCA | 10,000 | -6,10 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| RELAY THERAPEUTICS | 12,720 | -1,85 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer | Zovegalisib + atirmociclib + AI selected as triplet regimen for frontline development Compelling efficacy and tolerability data for zovegalisib triplet in median 3L patients 44% ORR in heavily pre-treated... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,960 | -3,05 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 36,630 | +2,35 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 323,50 | +1,46 % | Optimism Surrounds Praxis Precision Medicines (PRAX) Amid Potential FDA Approval for Ulixacaltamide | ||
| JANUX THERAPEUTICS | 14,340 | -0,21 % | Janux Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 55,23 | +2,70 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| CG ONCOLOGY | 66,21 | -0,79 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,960 | +10,73 % | Morning Market Movers: Sagimet Biosciences, Compass Therapeutics, Oruka Therapeutics, Veradermics See Big Swings | SAN DIEGO (dpa-AFX) - At 8:00 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 42,110 | +1,59 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| ZENAS BIOPHARMA | 19,360 | +0,21 % | Zenas BioPharma rises as CEO continues insider purchases | ||
| MINERALYS THERAPEUTICS | 29,300 | +9,94 % | Mineralys Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung und sieht Blockbuster-Potenzial | ||
| ANNEXON | 5,750 | -2,04 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | ARCHER II Topline Pivotal Phase 3 Data in Geographic Atrophy (GA) Expected Q4 2026; Vonaprument has Potential to Be the First Vision-Preserving Therapy for GA Tanruprubart MAA Filed in Europe with... ► Artikel lesen | |
| BEAM THERAPEUTICS | 30,700 | +1,22 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study |
Das Unternehmen VISEN PHARMACEUTICALS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,34 % bei einem Aktienkurs von 2,760 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VISEN PHARMACEUTICALS finden Sie auf Wallstreet Online.